pdm09 H1N1
The 2009 pandemic H1N1 strain; now endemic globally, with antibodies in 66% of US dairy workers limiting B3.13 spread.
Last refreshed: 12 May 2026 · Appears in 1 active topic
If pdm09 antibodies are limiting H5N1 cases in US dairy workers, what happens in populations where 2009 vaccine uptake was low?
Timeline for pdm09 H1N1
Found as neutralising antibodies in 66% of exposed dairy farm workers, potentially explaining sporadic human case rates
Pandemics and Biosecurity: B3.13 replicates better in human nasal tissue- Does immunity from the 2009 swine flu protect against H5N1 bird flu?
- A May 2026 NIH/NIAID study found 66% of US dairy workers carry pdm09 H1N1 antibodies that cross-react with B3.13 H5N1. Researchers believe this pre-existing immunity is the main reason human cases have stayed rare despite widespread cattle infection.Source: CDC Emerging Infectious Diseases
- What was the 2009 swine flu pandemic and how deadly was it?
- The 2009 H1N1 pandemic was declared by WHO on 11 June 2009. Estimates range from 150,000 to 575,000 deaths in the first year, before vaccines were widely available. The strain has circulated as a seasonal flu ever since.Source: WHO
- Why do some people have natural immunity to H5N1 bird flu?
- Prior infection or vaccination with pdm09 H1N1 produces cross-reactive antibodies that partially neutralise B3.13 H5N1. This immunity is not complete protection, but appears to explain the low human case count among heavily-exposed US dairy workers.Source: CDC Emerging Infectious Diseases
Background
pdm09 H1N1 is the influenza A(H1N1) strain responsible for the 2009 swine flu pandemic, which the World Health Organization declared on 11 June 2009 and lifted on 10 August 2010 after an estimated 150,000 to 575,000 deaths in the first year. The strain originated from a quadruple-reassortant virus combining North American swine, Eurasian swine, human, and avian influenza gene segments; its rapid spread across 214 countries before vaccine rollout established it as the first pandemic of the WHO's revised International Health Regulations era. Since 2010, pdm09 has circulated globally as a seasonal influenza strain, co-circulating annually with H3N2 and influenza B. It is included in the Northern and Southern hemisphere seasonal vaccine formulations each year.
The significance of pdm09 for the current H5N1 situation is immunological. A May 2026 CDC Emerging Infectious Diseases study (DOI: 10.3201/eid3205.260053) found that 66% of US dairy farm workers carry pre-existing neutralising antibodies against pdm09 H1N1 that cross-react with the B3.13 H5N1 genotype. The researchers propose this cross-reactive antibody prevalence as the leading hypothesis for why human H5N1 cases have remained sporadic — 71 confirmed in the United States — despite extensive cattle-to-worker exposure and evidence that B3.13 can now replicate efficiently in human nasal tissue.
The implication runs both ways. The pdm09 immunity ceiling may be protecting the US dairy workforce today; any population without comparable pdm09 exposure history — including populations where pdm09 vaccination coverage was low in 2009-2010 — would lack that protection. Global equity in pandemic H1N1 exposure is uneven, and that unevenness could become material if B3.13 achieves broader geographic spread.
